Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT00947388 · TERMINATED

Trial details

NCT number: NCT00947388
Sponsor: Case Comprehensive Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma

Start date: 2008-11-01
Primary completion: 2012-09-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.